Thymidine Kinase Inhibitors
1 drugsAbout Thymidine Kinase
Thymidine Kinase (TK) is an enzyme essential for DNA synthesis, catalyzing thymidine phosphorylation. It plays a crucial role in cell proliferation and DNA repair processes.
While there is currently no genetic evidence directly linking Thymidine Kinase to specific diseases, its role in DNA metabolism makes it a relevant target for inhibiting cell division.
Thymidine Kinase is targeted by one FDA-approved drug, Acyclovir, a small molecule used in 'other' therapeutic areas and marketed by Sun Pharma Canada.
Top Thymidine Kinase Drugs
Sun Pharma Canada is the only company with an approved drug targeting Thymidine Kinase.
Low competition suggests a potential market entry opportunity, but also indicates possible challenges in target validation.
Thymidine Kinase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Thymidine Kinase, using small molecule modality.
The lack of diverse modalities indicates a whitespace opportunity for novel therapeutic approaches targeting Thymidine Kinase.
Thymidine Kinase Clinical Trials 34 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Thymidine Kinase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 8 | 6 | 0 | 2 | 100% |
| Phase 2 | 6 | 5 | 1 | 0 | 83% |
| Phase 3 | 9 | 6 | 1 | 2 | 86% |
| Phase 4 | 11 | 5 | 2 | 4 | 71% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Thymidine Kinase Drug Approval Timeline (1997 - 1997)
The first and most recent drug approval for Thymidine Kinase was Acyclovir in 1997.
The lack of recent approvals suggests potential saturation or challenges in developing new Thymidine Kinase-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 29 (11 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Thymidine Kinase. A trial counts if an approved drug acting on Thymidine Kinase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.